IWO, AIT, CRS, HALO: ETF Inflow Alert
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy HALO?
Source: NASDAQ.COM
IWO Share Price Analysis: IWO's current share price is $240.15, with a 52-week low of $219.19 and a high of $317.62; the comparison to the 200-day moving average can provide further insights into its performance.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 66.350
Low
56.00
Averages
78.50
High
90.00
Current: 66.350
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
Global Collaboration Announcement: Haloyzime has announced a global collaboration and licensing agreement with GSK.
Focus on Oncology: The partnership aims to develop subcutaneous formulations targeting multiple promising oncology therapies.
See More
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
Halozyme Appoints New CFO Darren Snellgrove
- Executive Appointment: Halozyme Therapeutics has announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026; Snellgrove previously led investor relations at Johnson & Johnson and brings over 30 years of industry experience, which is expected to enhance the company's financial management and strategic planning capabilities.
- Financial Strategy Leadership: As the new CFO, Snellgrove will oversee Halozyme's financial operations and strategy, including capital allocation, corporate development, and investor relations, a move that could bolster the company's performance in capital markets and investor confidence.
- Industry Background: Snellgrove's experience at Johnson & Johnson has familiarized him with the financial operations of large pharmaceutical companies, and he is expected to leverage this experience to optimize Halozyme's financial structure and drive sustained growth in the biopharmaceutical sector.
- Future Outlook: With Snellgrove's arrival, Halozyme may achieve more efficient management in financial decision-making and strategic execution, thereby laying a solid foundation for the company's long-term development.
See More
Halozyme Appoints New Chief Financial Officer
- Executive Appointment: Halozyme announced the appointment of Darren Snellgrove as Chief Financial Officer effective June 8, 2026, who will lead the company's financial operations and strategy, expected to enhance capital allocation and investor relations efficiency.
- Extensive Experience: Snellgrove brings over 30 years of financial leadership experience, having previously led investor relations at Johnson & Johnson, where he successfully reshaped corporate messaging and investor engagement strategies, strengthening analyst and shareholder relationships.
- Strategic Impact: As CFO of Johnson & Johnson's Pharmaceuticals sector, Snellgrove provided global financial leadership for a business generating over $50 billion in annual revenue, driving significant investments across commercial operations, R&D, and business development.
- Technological Innovation: Halozyme's ENHANZE® technology has been commercialized globally, improving the delivery of biologics, and Snellgrove's addition is expected to further drive sustainable growth and shareholder value creation.
See More
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
Global Collaboration Announcement: Haloyzime has announced a global collaboration and licensing agreement with GSK.
Focus on Oncology: The partnership aims to develop subcutaneous formulations targeting multiple promising oncology therapies.
See More
Halozyme to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Halozyme Therapeutics will release its Q1 2026 financial and operating results on May 11, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss the results, providing a convenient online registration link, which highlights its focus on investor relations.
- Technological Innovation Expansion: Halozyme's ENHANZE® drug delivery technology has impacted over one million patients across more than 100 global markets, indicating its broad application and market recognition in the biopharmaceutical sector.
- New Technology Partnerships: The collaboration with Hypercon™ and Surf Bio further expands the drug delivery technology portfolio, signaling a new standard for drug administration in home and healthcare settings, thereby enhancing market competitiveness.
See More
Halozyme Appoints New CFO Darren Snellgrove
- Executive Appointment: Halozyme Therapeutics has announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026; Snellgrove previously led investor relations at Johnson & Johnson and brings over 30 years of industry experience, which is expected to enhance the company's financial management and strategic planning capabilities.
- Financial Strategy Leadership: As the new CFO, Snellgrove will oversee Halozyme's financial operations and strategy, including capital allocation, corporate development, and investor relations, a move that could bolster the company's performance in capital markets and investor confidence.
- Industry Background: Snellgrove's experience at Johnson & Johnson has familiarized him with the financial operations of large pharmaceutical companies, and he is expected to leverage this experience to optimize Halozyme's financial structure and drive sustained growth in the biopharmaceutical sector.
- Future Outlook: With Snellgrove's arrival, Halozyme may achieve more efficient management in financial decision-making and strategic execution, thereby laying a solid foundation for the company's long-term development.
See More
Halozyme Appoints New Chief Financial Officer
- Executive Appointment: Halozyme announced the appointment of Darren Snellgrove as Chief Financial Officer effective June 8, 2026, who will lead the company's financial operations and strategy, expected to enhance capital allocation and investor relations efficiency.
- Extensive Experience: Snellgrove brings over 30 years of financial leadership experience, having previously led investor relations at Johnson & Johnson, where he successfully reshaped corporate messaging and investor engagement strategies, strengthening analyst and shareholder relationships.
- Strategic Impact: As CFO of Johnson & Johnson's Pharmaceuticals sector, Snellgrove provided global financial leadership for a business generating over $50 billion in annual revenue, driving significant investments across commercial operations, R&D, and business development.
- Technological Innovation: Halozyme's ENHANZE® technology has been commercialized globally, improving the delivery of biologics, and Snellgrove's addition is expected to further drive sustainable growth and shareholder value creation.
See More
